Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition

Permanent lenke
https://hdl.handle.net/10037/17282
DOI
https://doi.org/10.1161/CIRCGEN.118.002335
Thumbnail
Åpne
Akseptert manusversjon (PDF)
Dato
2019-01-15
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Brumpton, Ben Michael; Fritsche, Lars; Zheng, Jie; Nielsen, Jonas Bille; Mannila, Maria Nastase; Surakka, Ida; Rasheed, Humaira; Vie, Gunnhild Åberge; Graham, Sarah E.; Gabrielsen, Maiken Elvestad; Laugsand, Lars Erik; Aukrust, Pål; Vatten, Lars Johan; Damås, Jan Kristian; Ueland, Thor; Janszky, Imre; Zwart, John-Anker; van't Hooft, Ferdinand M.; Seidah, Nabil Georges; Hveem, Kristian; Willer, Cristen; Smith, George Davey; Åsvold, Bjørn Olav
Sammendrag
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 inhibition.
Forlag
American Heart Association
Sitering
Brumpton BM, Fritsche L, Zheng J, Nielsen JB, Mannila MN, Surakka I, Rasheed H, Vie GÅ, Graham SE, Gabrielsen ME, Laugsand LE, Aukrust P, Vatten LJ, Damås JK, Ueland T, Janszky I, Zwart J, van't Hooft, Seidah, Hveem K, Willer C, Smith GD, Åsvold BO. Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition. Circulation. Genomic and precision medicine. 2019;12:e002335(1)
Metadata
Vis full innførsel
Samlinger
© 2019 American Heart Association, Inc.